# Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

> **NCT05743244** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 78 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Abrocitinib 200 MG Oral Tablet
- **DRUG:** Ritlecitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05743244
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-19
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2025-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05743244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05743244, "Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05743244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*